Free Trial
NASDAQ:RNAC

Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Cartesian Therapeutics logo
$9.74 -0.26 (-2.60%)
Closing price 04:00 PM Eastern
Extended Trading
$9.70 -0.04 (-0.41%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cartesian Therapeutics Stock (NASDAQ:RNAC)

Advanced

Key Stats

Today's Range
$9.38
$10.02
50-Day Range
$9.15
$12.85
52-Week Range
$8.46
$26.50
Volume
97,131 shs
Average Volume
81,379 shs
Market Capitalization
$253.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Moderate Buy

Company Overview

Cartesian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

RNAC MarketRank™: 

Cartesian Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 659th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Cartesian Therapeutics has a consensus price target of $40.00, representing about 310.7% upside from its current price of $9.74.

  • Amount of Analyst Coverage

    Cartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cartesian Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    27.64% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cartesian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cartesian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.64% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 35.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving.
  • News Sentiment

    Cartesian Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cartesian Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    60.30% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cartesian Therapeutics' insider trading history.
Receive RNAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RNAC Stock News Headlines

Cartesian Therapeutics Insider Ups Holding During Year
Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
See More Headlines

RNAC Stock Analysis - Frequently Asked Questions

Cartesian Therapeutics' stock was trading at $17.91 at the start of the year. Since then, RNAC shares have decreased by 45.6% and is now trading at $9.74.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its quarterly earnings data on Thursday, August, 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $1.26. The company earned $0.30 million during the quarter, compared to analyst estimates of $0.77 million.

Cartesian Therapeutics's stock reverse split on the morning of Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/07/2025
Today
10/07/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNAC
Previous Symbol
NASDAQ:RNAC
CIK
1453687
Employees
64
Year Founded
2016

Price Target and Rating

High Price Target
$42.00
Low Price Target
$38.00
Potential Upside/Downside
+311.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($52.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
2.13
P/E Growth
N/A
Net Income
-$77.42 million
Net Margins
N/A
Pretax Margin
-3,506.15%
Return on Equity
N/A
Return on Assets
-6.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.33
Quick Ratio
13.33

Sales & Book Value

Annual Sales
$1.03 million
Price / Sales
246.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
-36.02

Miscellaneous

Outstanding Shares
26,002,000
Free Float
10,323,000
Market Cap
$252.87 million
Optionable
Optionable
Beta
0.39

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:RNAC) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners